Seeking Alpha

GlaxoSmithKline's (GSK) Revolade received draft guidance support from the National Institute for...

GlaxoSmithKline's (GSK) Revolade received draft guidance support from the National Institute for Health and Clinical Excellence - the financial watchdog for the U.K health system - which overturns a 2010 ruling that said the drug was too costly. The drug is a treatment for a rare disorder called chronic immune thrombocytopenic purpura, and occurs in patients who have had their spleens removed. GSK received the institute's stamp of approval after agreeing to sell it to the state-run medical system at a discount.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|